臨床検査53巻1号

2009年01月発行

記事購入ページに移動

今月の主題 ウイルス感染症─最新の動向 各論 〈感染症ごとにみたウイルス感染症の診断と対策〉

B型・C型ウイルス性肝炎

著者： 芥田憲夫¹ 熊田博光¹

所属機関： ¹虎の門病院肝臓センター

ページ範囲：P.53 - P.60

　本稿ではB型・C型肝炎における最新の治療ガイドラインを示す．まず，B型慢性肝炎の若年例はinterferon(IFN)長期あるいはentecavir(ETV)が原則で，中高年例の核酸アナログ未使用例もETVが第一選択である．C型慢性肝炎の初回治療例で，高ウイルス量はPEG-IFN・リバビリン(RBV)併用療法，低ウイルス量はIFN単独療法が第一選択である．B型・C型肝炎の治療は各種薬剤の長所・短所を十分理解したうえで，生命予後を改善できる治療を選択していく必要がある．

参考文献

1) 熊田博光：厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業(肝炎分野)．肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究 平成19年度総括・分担研究報告書，2008

2) Lin SM, Yu ML, Lee CM, et al：Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol　46：45-52. 2007

3) Liaw YF, Sung JJ, Chow WC, et al：Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med　351：1521-1531, 2004

4) Matsumoto A, Tanaka E, Rokuhara A, et al：Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B：A multicenter retrospective study of 2795 patients. Hepatol Res　32：173-184, 2005

5) Lamperitico P, Viganò M, Manenti E, et al：Low resistance to adefovir combined with lamivudine：A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology　133：1445-1451, 2007

6) Yatsuji H, Suzuki F, Sezaki H, et al：Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy：Two-year follow-up. J Hepatol　48：923-931, 2008

7) Villet S, Pichoud C, Billioud G, et al：Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol　48：747-755, 2008

8) Yatusji H, Hiraga N, Mori N, et al：Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol　79：1811-1817, 2007

9) Villet S, Ollivet A, Pichoud C, et al：Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol　46：531-538, 2007

10) Colonno RJ, Rose R, Baldick CJ, et al：Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology　44：1656-1665, 2006

11) Suzuki F, Akuta N, Suzuki Y, et al：Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol　39：149-152, 2007

12) Chang TT, Gish RG, de Man R, et al：A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med　354：1001-1010, 2006

13) Lai CL, Shouval D, Lok AS, et al：Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med　354：1011-1020, 2006

14) Akuta N, Suzuki F, Kawamura Y, et al：Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b：amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol　46：403-410, 2007

15) Akuta N, Suzuki F, Kawamura Y, et al：Predictors of viral kinetics to peginteferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol　79：1686-1695, 2007

16) Enomoto N, Sakuma I, Asahina Y, et al：Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest　96：224-230, 1995

17) Enomoto N, Sakuma I, Asahina Y, et al：Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med　334：77-81, 1996

18) Akuta N, Suzuki F, Kawamura Y, et al：Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. J Med Virol　80：1363-1369, 2008

19) Akuta N, Suzuki F, Kawamura Y, et al：Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology　46：1357-1364, 207

20) Akuta N, Suzuki F, Kawamura Y, et al：Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. J Med Virol　80：1354-1362, 2008

21) Moriya K, Fujie H, Shintani Y, et al：The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine　4：1065-1067, 1998